NCT06045975
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06045975
Title Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)
Acronym DUMELEP
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Assistance Publique - Hôpitaux de Paris
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.